IP Library Patent Application 18972484
Patent Application
App. No. 18/972,484

USE OF AMISULPRIDE AS AN ANTI-EMETIC

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/972,484
Abstract

Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.

Claims (15)

1 . A method for the prevention and/or treatment of post-operative nausea and vomiting, comprising administering amisulpride at a dose of 1 mg to 35 mg to a human subject of a surgical procedure and in need of such prevention and/or treatment, wherein the amisulpride is administered in combination with another anti-emetic drug.

2 . The method according to claim 1 , wherein the human subject is also administered an emetogenic agent.

3 . The method according to claim 2 , wherein the emetogenic agent is an opiate.

4 . The method according to claim 2 , wherein the emetogenic agent is morphine.

5 . The method according to claim 1 , wherein the human subject is also administered an anesthetic.

6 . The method according to claim 1 , wherein the other anti-emetic drug administered in combination with the amisulpride is a 5HT3 antagonist, an NK1 antagonist, or a steroid.

7 . The method of claim 6 , wherein the other anti-emetic administered in combination with the amisulpride is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant, or rolapitant.

8 . The method according to claim 6 , wherein the 5HT3 antagonist is ondansetron.

9 . The method of claim 1 , wherein the amisulpride is administered in the form of a pharmaceutical composition comprising amisulpride, citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride.

10 . The method of claim 9 , wherein the pharmaceutical composition comprises 0.25% w/v amisulpride.

11 . The method of claim 9 , wherein the pharmaceutical composition comprises 0.25% w/v amisulpride, 0.935% w/v citric acid monohydrate, 1.632% w/v trisodium citrate dihydrate, and 0.18% w/v sodium chloride.

12 . The method of claim 1 , wherein the amisulpride is S-amisulpride.

13 . The method of claim 1 , wherein the amisulpride is administered intravenously.

14 . The method of claim 1 , for the prevention of post-operative nausea and vomiting.

15 . The method of claim 1 , for the treatment of post-operative nausea and vomiting.

Assignments (3)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2026
From: ACACIA PHARMA LIMITED; ACACIA PHARMA, INC.; EAGLE PHARMACEUTICALS, INC.
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY; LXO US, INC.
Reel/Frame 073967/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2026
From: GILBERT, JULIAN CLIVE; GRISTWOOD, ROBERT WILLIAM; COOPER, NICCOLA; FOX, GABRIEL
To: ACACIA PHARMA LIMITED
Reel/Frame 073853/0941 →